What is The Prostatype Genomic ClassifierTM?
If you have been diagnosed with localized, non-metastatic prostate cancer, in other words cancer that has not spread outside the prostate, The Prostatype Genomic Classifier can help you and your doctor choose the right treatment.
The test helps determine if your cancer is aggressive or non-aggressive, and if you may safely forego surgery and/or radiation therapy.
The test provides a personalized assessment to help guide you and your doctor in making the most informed decisions for your care.
What is Prostatype?
If you have been diagnosed with localized, non metastatic prostate cancer, in other words cancer that has not spreads outside the prostate, Prostatype® can help you and your doctor choose the right treatment.
The test helps determine if your cancer is aggressive or non-aggressive, and if you may safely forego surgery and/or radiation therapy.
The test provides a personalized assessment to help guide you and your doctor in making the most informed decisions for your care.
Prostatype® Defines Your Tumor’s Unique Biology
The Prostatype test measures the expression of three genes that have been strongly linked to prostate cancer aggressiveness.
Prostatype uses the tumor tissue from your previous prostate biopsy, eliminating the need for another invasive procedure. Beyond discussing and deciding with your doctor if the Prostatype test is right for you, there is nothing further you need to do to have this test performed.
Knowing your individual risk helps you and your urologist decide if active surveillance, surgery or radiation treatment is necessary.
Ask your doctor about The Prostatype Genomic Classifier to help you determine if Active Surveillance is right for you.
Localized prostate cancer can often be low-risk, non-aggressive and studies have shown that certain patients can safely delay or potentially even eliminate the need for treatment. Such patients are candidates for active surveillance, which includes regular doctor visits and ongoing observation.
It is also important to understand that due to known sampling error your biopsy could have missed the most aggressive tumor in your prostate. Prostatype helps determine if that has occurred to you.
Prostatype has been shown to improve the identification of patients who may have undetected aggressive disease, patients who have an increased risk of metastases (spread of cancer during the next 5 to 10 years), and those whose cancer has a higher probability of causing death due to prostate cancer. These patients should consider getting treatment with curative intent.
Prostatype® Results Empower Your Decision
Prostatype provides insights into your risk for adverse pathology, metastasis, and mortality, to help you decide what is best for you.
Frequently Asked Questions
If you have been diagnosed with localized prostate cancer and have not been treated with surgery or radiation therapy, the Prostatype Genomic Classifier may be helpful for you. The test is not indicated for men diagnosed with advanced prostate cancer.
If you have been diagnosed with localized prostate cancer and you have chosen or you are considering active surveillance, you may be eligible for the Prostatype Genomic Classifier. The test must be ordered prior to radical prostatectomy, radiation therapy, or other definitive treatment.
After receiving the tissue sample from your biopsy, it usually takes our laboratory approximately 10-12 days to perform the test. Once the Prostatype report is ready, it will be sent to your doctor. They will contact you to discuss the results and provide their treatment recommendations.
Importantly, only your physician can order the Prostatype test for you.
Please follow this link to our Contact page where you can request additional information about the Prostatype test and ask for a company representative to speak with your doctor.
Our laboratory will send an invoice to your insurance provider for payment. In most cases, insurance companies will cover the entire testing fee. Prostatype Genomics will accept the payment from your insurance company as payment in full with a signed Assignment of Benefits form (AOB). Prostatype Genomics will not balance bill you for the difference between the insurance payment and the retail price of the test, however, your insurance provider may direct us to collect your co-pay or deductible from you.
Frequently Asked Questions
If you have been diagnosed with localized prostate cancer and have not been treated with surgery or radiation therapy, the Prostatype Genomic Classifier may be helpful for you. The test is not indicated for men diagnosed with advanced prostate cancer.
If you have been diagnosed with localized prostate cancer and you have chosen or you are considering active surveillance, you may be eligible for the Prostatype Genomic Classifier. The test must be ordered prior to radical prostatectomy, radiation therapy, or other definitive treatment.
After receiving the tissue sample from your biopsy, it usually takes our laboratory approximately 10-12 days to perform the test. Once the Prostatype report is ready, it will be sent to your doctor. They will contact you to discuss the results and provide their treatment recommendations.
Importantly, only your physician can order the Prostatype test for you.
Please follow this link to our Contact page where you can request additional information about the Prostatype test and ask for a company representative to speak with your doctor.
Our laboratory will send an invoice to your insurance provider for payment. In most cases, insurance companies will cover the entire testing fee. Prostatype Genomics will accept the payment from your insurance company as payment in full with a signed Assignment of Benefits form (AOB). Prostatype Genomics will not balance bill you for the difference between the insurance payment and the retail price of the test, however, your insurance provider may direct us to collect your co-pay or deductible from you.
Before Deciding Know Your Prostatype!